Print Page   |   Contact Us   |   Sign In   |   Register
Pharmacy Meeting (Health Policy Update: Prescription Drug Pricing)
Tell a Friend About This EventTell a Friend
Pharmacy Meeting (Health Policy Update: Prescription Drug Pricing)

When: Tuesday, March 12, 2019
From 2:00 PM to 4:00 PM
Where: BHC Large Conference Room
8888 Ladue Road
Suite 250
St. Louis, Missouri  63124
United States

Online registration is closed.
« Go to Upcoming Event List  

Tuesday, March 12, 2019

2:00 PM - 4:00 PM

BHC Large Conference Room

Health Policy Update: Prescription Drug Pricing

The pharmaceutical industry continues to make headlines for egregious pricing strategies, with sixty manufacturers celebrating the start of 2019 by raising list prices on nearly 300 drugs. This follows the 2,100 price inflations that occurred last year, with a median increase amount of 9%. In response, President Trump and Secretary Alex Azar of the U.S. Department of Health and Human Services released a drug pricing blueprint (American Patients First) in May 2018, which includes provisions for an international reference pricing system, as well as the inclusion of pharmaceutical list prices in television advertising. But many questions still remain for payers: Is this all talk and no action? How could the Affordable Care Act, Food & Drug Administration, and patent litigation impact progress? And what changes should employers be prepared for moving forward?


For this BHC Pharmacy Meeting, we welcome Rachel Sachs, Associate Professor of Law with Washington University, to provide a health policy update on prescription drug pricing. Ms. Sachs’ work, which has been featured in national media outlets and peer-reviewed journals, explores questions of innovation and access in the health care field and how the law can help or hinder future advancement.

2:00 PM Welcome and Introductions
2:15 PM

Health Policy Update: Prescription Drug Pricing
Rachel Sachs, Associate Professor of Law, Washington University

  • Update on recent regulatory and legislative actions in the drug pricing space and how the pharmaceutical industry is responding, including:
    • American Patients First blueprint
    • Texas v. Azar court ruling and the Affordable Care Act
    • Food & Drug Administration’s Biosimilar Action Plan
    • Patent litigation delays
  • Discuss changes that employers can expect moving forward, as well as tools that payers have to address drug price increases.
3:45 PM Member Dialogue & Questions
4:00 PM Adjourn

Membership Management Software Powered by YourMembership  ::  Legal